Cargando…
A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development
The rapid rise of antibiotic resistance is a serious threat to global public health. The situation is exacerbated by the “antibiotics dilemma”: Developing narrow-spectrum antibiotics against resistant bacteria is most beneficial for society, but least attractive for companies, since their usage and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023703/ https://www.ncbi.nlm.nih.gov/pubmed/35451653 http://dx.doi.org/10.1007/s11538-022-01013-7 |
_version_ | 1784690401425227776 |
---|---|
author | Böttcher, Lucas Gersbach, Hans |
author_facet | Böttcher, Lucas Gersbach, Hans |
author_sort | Böttcher, Lucas |
collection | PubMed |
description | The rapid rise of antibiotic resistance is a serious threat to global public health. The situation is exacerbated by the “antibiotics dilemma”: Developing narrow-spectrum antibiotics against resistant bacteria is most beneficial for society, but least attractive for companies, since their usage and sales volumes are more limited than for broad-spectrum drugs. After developing a general mathematical framework for the study of antibiotic resistance dynamics with an arbitrary number of antibiotics, we identify efficient treatment protocols. Then, we introduce a market-based refunding scheme that incentivizes pharmaceutical companies to develop new antibiotics against resistant bacteria and, in particular, narrow-spectrum antibiotics that target specific bacterial strains. We illustrate how such a refunding scheme can solve the antibiotics dilemma and cope with various sources of uncertainty that impede antibiotic R &D. Finally, connecting our refunding approach to the recently established Antimicrobial Resistance (AMR) Action Fund, we discuss how our proposed incentivization scheme could be financed. |
format | Online Article Text |
id | pubmed-9023703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-90237032022-04-22 A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development Böttcher, Lucas Gersbach, Hans Bull Math Biol Original Article The rapid rise of antibiotic resistance is a serious threat to global public health. The situation is exacerbated by the “antibiotics dilemma”: Developing narrow-spectrum antibiotics against resistant bacteria is most beneficial for society, but least attractive for companies, since their usage and sales volumes are more limited than for broad-spectrum drugs. After developing a general mathematical framework for the study of antibiotic resistance dynamics with an arbitrary number of antibiotics, we identify efficient treatment protocols. Then, we introduce a market-based refunding scheme that incentivizes pharmaceutical companies to develop new antibiotics against resistant bacteria and, in particular, narrow-spectrum antibiotics that target specific bacterial strains. We illustrate how such a refunding scheme can solve the antibiotics dilemma and cope with various sources of uncertainty that impede antibiotic R &D. Finally, connecting our refunding approach to the recently established Antimicrobial Resistance (AMR) Action Fund, we discuss how our proposed incentivization scheme could be financed. Springer US 2022-04-22 2022 /pmc/articles/PMC9023703/ /pubmed/35451653 http://dx.doi.org/10.1007/s11538-022-01013-7 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Böttcher, Lucas Gersbach, Hans A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development |
title | A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development |
title_full | A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development |
title_fullStr | A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development |
title_full_unstemmed | A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development |
title_short | A Refunding Scheme to Incentivize Narrow-Spectrum Antibiotic Development |
title_sort | refunding scheme to incentivize narrow-spectrum antibiotic development |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023703/ https://www.ncbi.nlm.nih.gov/pubmed/35451653 http://dx.doi.org/10.1007/s11538-022-01013-7 |
work_keys_str_mv | AT bottcherlucas arefundingschemetoincentivizenarrowspectrumantibioticdevelopment AT gersbachhans arefundingschemetoincentivizenarrowspectrumantibioticdevelopment AT bottcherlucas refundingschemetoincentivizenarrowspectrumantibioticdevelopment AT gersbachhans refundingschemetoincentivizenarrowspectrumantibioticdevelopment |